2016/1 GaBI Journal Table of Contents

Contents

Editor’s Letter

Editor’s introduction to the initial issue of the fifth volume of GaBI Journal

Letters to the Editor

First biosimilar of infliximab approved in Brazil: response from the Brazilian IBD society

Commentary

Low-cost generic drug programs in the US: implications for payers and researchers

Waiver of consent for retrospective chart review studies

Original Research

Views of physicians and patients with chronic conditions on generic medicines in Greece after the introduction of measures to promote their consumption: findings from a qualitative study

Review Article

Life begins at forty – hybridomas: ageing technology holds promise for future drug discoveries

Regulatory

Pricing of Biosimilars in Saudi Arabia

The EU is ready for non-biological complex medicinal products

Special Report

Complexity in the making: non-biological complex drugs (NBCDs) and the pharmacopoeias

Pharma News

Top developments in biosimilars during 2015

Abstracted Scientific Content

Promoting a competitive generics market in the US

The case for reforming drug naming

Source URL: https://gabi-journal.net/20161-gabi-journal-table-of-contents.html